Secretome profiling of Artemisia absinthium extract-loaded polymeric nanoparticle-treated MCF-7 and MDA-MB-231 revealed perturbation in microtubule assembly and cell migration
Authors:
Open Access
- 31 August 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1209168
Abstract
Introduction: Artemisia absinthium (wormwood) exhibits anticancer properties by inhibiting proliferation and causing cell death in breast cancer. Targeted drug delivery of A. absinthium nanoformulation using N-isopropyl acrylamide, N-vinyl pyrrolidone, and acrylic acid-based polymeric nanoparticles (NVA-AA NPs) was ensured by utilizing features of the tumor microenvironment, although their mechanism of action involved in cytotoxicity remains unknown.Methods: The present study employed nano LC-MS/MS to identify differences in secretory protein expression associated with the treatment of breast cancer cell lines (MCF-7; MDA-MB-231) by NVA-AA NPs for the determination of affected pathways and easily accessible therapeutic targets. Different bioinformatics tools were used to identify signature differentially expressed proteins (DEPs) using survival analysis by GENT2 and correlation analysis between their mRNA expressions and sensitivity toward small-molecule drugs as well as immune cell infiltration by GSCA.Results: Analysis by GENT2 revealed 22 signature DEPs with the most significant change in their expression regulation, namely, gelsolin, alpha-fetoprotein, complement component C3, C7, histone H2B type 1-K, histone H2A.Z, H2AX, heat shock cognate 71 kDa protein, heat shock 70 kDa protein 1-like, cytochrome c somatic, GTP-binding nuclear protein Ran, tubulin beta chain, tubulin alpha-1B chain, tubulin alpha-1C chain, phosphoglycerate mutase 1, kininogen 1, carboxypeptidase N catalytic chain, fibulin-1, peroxiredoxins 4, lactate dehydrogenase C, SPARC, and SPARC-like protein 1. Correlation analysis between their mRNA expressions versus immune cell infiltrates showed a positive correlation with antitumor immune response elicited by these NPs as well as a correlation with drug response shown by the GDSC and CTRP drugs in different cancer cells.Discussion: Our results suggest that NVA-AA NPs were able to invade the tumor microenvironment; transformed the communication network between the cancer cells; affected potential drivers of microtubular integrity, nucleosome assembly, and cell cycle; and eventually caused cell death.Keywords
Funding Information
- Council of Scientific and Industrial Research, India (09/591(0158)/2018-EMR-I, 09/591(0159)/2018-EMR-I)
- Indian Council of Medical Research (45/25/2018-NAN/BMS)
This publication has 101 references indexed in Scilit:
- Early diagnostic protein biomarkers for breast cancer: how far have we come?Breast Cancer Research and Treatment, 2011
- Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancerBMC Medical Genomics, 2010
- Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive valueBritish Journal of Cancer, 2010
- Systematic analysis, comparison, and integration of disease based human genetic association data and mouse genetic phenotypic informationBMC Medical Genomics, 2010
- The effect of thrombospondin-1 on breast cancer metastasisBreast Cancer Research and Treatment, 2008
- SPARC‐induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretionInternational Journal of Cancer, 2008
- Breast Tumor Microenvironment: Proteomics Highlights the Treatments Targeting SecretomeJournal of Proteome Research, 2008
- Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancerClinical & Experimental Metastasis, 2007
- Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistanceBreast Cancer Research and Treatment, 2006
- Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10British Journal of Cancer, 2003